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Abstract
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) receptors
(nomenclature as agreed by the NC-IUPHAR Subcommittee on Vasoactive Intestinal Peptide Receptors
[64, 65]) are activated by the endogenous peptides VIP, PACAP-38, PACAP-27, peptide histidine
isoleucineamide (PHI), peptide histidine methionineamide (PHM) and peptide histidine valine (PHV). VPAC1 and
VPAC2 receptors display comparable affinity for the PACAP peptides, PACAP-27 and PACAP-38, and VIP,
whereas PACAP-27 and PACAP-38 are >100 fold more potent than VIP as agonists of most isoforms of the
PAC1 receptor. However, one splice variant of the human PAC1 receptor has been reported to respond to
PACAP-38, PACAP-27 and VIP with comparable affinity [29]. PG 99-465 [115] has been used as a selective
VPAC2 receptor antagonist in a number of physiological studies, but has been reported to have significant
activity at VPAC1 and PAC1 receptors [35]. The selective PAC1 receptor agonist maxadilan, was extracted from
the salivary glands of sand flies (Lutzomyia longipalpis) and has no sequence homology to VIP or the PACAP
peptides [116]. Two deletion variants of maxadilan, M65 [180] and Max.d.4 [117] have been reported to be PAC1
receptor antagonists, but these peptides have not been extensively characterised.
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